Soegiharto, R. Et Al. 2025. Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study. Allergy: European Journal of Allergy and Clinical Immunology , vol.80, no.2 , 489-499.

Soegiharto, R., Alizadeh Aghdam, M., Sørensen, J., van Lindonk, E., Bulut Demir, F., Mohammad Porras, N., ... Matsuo, Y.(2025). Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study. Allergy: European Journal of Allergy and Clinical Immunology , vol.80, no.2, 489-499.

Soegiharto, R. Et Al. "Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study," Allergy: European Journal of Allergy and Clinical Immunology , vol.80, no.2, 489-499, 2025

Soegiharto, R. Et Al. "Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study." Allergy: European Journal of Allergy and Clinical Immunology , vol.80, no.2, pp.489-499, 2025

Soegiharto, R. Et Al. (2025) . "Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study." Allergy: European Journal of Allergy and Clinical Immunology , vol.80, no.2, pp.489-499.

@article{article, author={R. Soegiharto Et Al. }, title={Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study}, journal={Allergy: European Journal of Allergy and Clinical Immunology}, year=2025, pages={489-499} }